Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target by Oppenheimer Holdings, Inc. Analysts
Global Blood Therapeutics, Inc. (NASDAQ:GBT) has been assigned a $53.00 price objective by Oppenheimer Holdings, Inc. in a report released on Monday. The brokerage currently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s target price points to a potential upside of 37.84% from the company’s current price.
Several other equities research analysts have also issued reports on GBT. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Cowen and Company reiterated a “buy” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research note on Thursday. J P Morgan Chase & Co reiterated an “overweight” rating and set a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a research note on Tuesday, August 8th. Finally, SunTrust Banks, Inc. raised their target price on Global Blood Therapeutics to $67.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $55.00.
Shares of Global Blood Therapeutics (NASDAQ:GBT) traded down $0.70 during mid-day trading on Monday, reaching $38.45. The company had a trading volume of 466,200 shares, compared to its average volume of 1,112,269. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $43.95.
Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the prior year, the business earned ($0.58) earnings per share. equities analysts predict that Global Blood Therapeutics will post -2.49 EPS for the current fiscal year.
WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/11/13/global-blood-therapeutics-inc-gbt-given-a-53-00-price-target-by-oppenheimer-holdings-inc-analysts.html.
In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 141,655 shares in the company, valued at $4,249,650. The disclosure for this sale can be found here. Insiders sold a total of 91,500 shares of company stock worth $3,093,350 over the last ninety days. Insiders own 5.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its holdings in Global Blood Therapeutics by 140.0% in the first quarter. Morgan Stanley now owns 334,872 shares of the company’s stock worth $12,340,000 after acquiring an additional 195,323 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in Global Blood Therapeutics in the second quarter worth $4,103,000. Emory University bought a new stake in Global Blood Therapeutics in the second quarter worth $1,442,000. Marcus Capital LLC boosted its holdings in Global Blood Therapeutics by 25.7% in the second quarter. Marcus Capital LLC now owns 65,350 shares of the company’s stock worth $1,787,000 after acquiring an additional 13,350 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in Global Blood Therapeutics by 1,544.9% in the second quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock worth $2,402,000 after acquiring an additional 82,480 shares in the last quarter. 86.76% of the stock is currently owned by institutional investors and hedge funds.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.